SRZN Stock Summary and Trading Ideas (Surrozen | NASDAQ:SRZN)

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).

Surrozen trades on the NASDAQ stock market under the symbol SRZN.

As of September 10, 2026, SRZN stock price declined to $19.45 with 260,302 million shares trading.

SRZN has a beta of 1.12, meaning it tends to be more sensitive to market movements. SRZN has a correlation of 0.04 to the broad based SPY ETF.

SRZN has a market cap of $228.61 million. This is considered a Small Cap stock.

Last quarter Surrozen reported $5 million in Revenue and -$.41 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.87.

In the last 3 years, SRZN traded as high as $35.00 and as low as $4.50.

The top ETF exchange traded funds that SRZN belongs to (by Net Assets): VTI, VXF, IWO, VTWO, GSSC.

SRZN has outperformed the market in the last year with a return of +66.2%, while the SPY ETF gained +17.7%. However, in the most recent history, SRZN shares have underperformed the stock market with its stock returning -9.5% in the last 3 month period and -18.0% for the last 2 week period, while SPY has returned +3.1% and -1.1%, respectively.

SRZN support price is $18.98 and resistance is $21.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRZN shares will trade within this expected range on the day.